United Therapeutics Corporation (UTHR) Stock Analysis
Is UTHR a good investment?
United Therapeutics Corporation (UTHR) has a Plutrex AI rating of 72.5/100 as of May 26, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: Exceptional profitability with 88.6% gross margins and 20.0% ROE in loss-making industry. Main concern: PEG ratio 1.52 suggests overvaluation with growth expectations already priced in.
Investment Summary
UTHR represents a rare profitable biotech with exceptional fundamentals but concerning valuation. ROE of 20.0% (vs industry -39.0%) and 88.6% gross margins demonstrate pricing power, while debt-free balance sheet with $2.77B cash provides fortress-like stability. However, PEG ratio of 1.52 suggests overvaluation, and forward EPS growth of 10.3% trails historical 12.1%. Recent positive news includes board appointment of prominent medical researcher Dr. Kevin Tracey and Phase 1 results for subsidiary Miromatrix's liver assist product, validating R&D strategy.
Key Strengths
- Exceptional profitability with 88.6% gross margins and 20.0% ROE in loss-making industry
- Debt-free balance sheet with $2.77B cash providing strategic flexibility and recession resilience
- Proven business model generating $734.6M free cash flow while peers burn cash
Key Concerns
- PEG ratio 1.52 suggests overvaluation with growth expectations already priced in
- Decelerating growth trajectory with forward EPS growth 10.3% below historical 12.1%
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
Outstanding profitability metrics dominate: gross margin 88.6% (vs industry 79.3%), operating margin 48.7% (vs industry -2,502%), net margin 40.6% (vs industry -916%), and ROE 20.0% (vs industry -39.0%). Financial fortress with zero debt (vs industry 1.17 D/E) and $2.77B cash. Growth concerns emerge with revenue growth 6.8% (vs industry 2,214%) and forward EPS growth 10.3% (vs industry 17.0%). PE ratio 18.11 appears reasonable but PEG 1.52 indicates premium pricing relative to growth expectations.
News Sentiment
United Therapeutics is making strategic moves to strengthen its biotechnology leadership position through key appointments and promising research developments. The company recently welcomed Dr. Kevin J. Tracey, a distinguished medical research figure and President of The Feinstein Institutes for Medical Research, to its Board of Directors in January 2026. This appointment signals UTHR's commitment to advancing its scientific capabilities and validates its position as a serious player in the biotech space. Meanwhile, the company announced positive Phase 1 results for miroliverELAP, an innovative external liver assist product developed by its wholly-owned subsidiary Miromatrix Medical. This development showcases UTHR's successful acquisition strategy and demonstrates how the company is expanding beyond its core business into adjacent therapeutic areas. The positive clinical results suggest the company's R&D investments are paying off, potentially opening new revenue streams in the critical care market. For investors, these developments reinforce UTHR's reputation as one of the few profitable biotechnology companies that combines financial stability with genuine innovation, setting it apart from the cash-burning competitors that dominate the industry.
Risk Assessment
Primary risk is valuation premium with PEG 1.52 requiring flawless execution. Growth deceleration from 12.1% historical to 10.3% forward could disappoint growth-focused investors. Biotech sector volatility and regulatory risks remain. Mitigation: exceptional balance sheet provides downside protection, and quality premium justified by consistent profitability in volatile sector.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is UTHR a halal stock?
No, United Therapeutics Corporation (UTHR) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for UTHR?
United Therapeutics Corporation (UTHR) has a Plutrex AI rating of 72.5/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is UTHR a good investment?
According to Plutrex AI, UTHR has a Buy rating (72.5/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in UTHR?
US stocks like UTHR can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in UTHR?
Plutrex AI identifies the main risks for UTHR by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.